Anaphylaxis to vaccination and polyethylene glycol: a perspective from the European Anaphylaxis Registry

To the Editor,

The COVID-19 pandemic is currently one of the most important health challenges, and the recently approved vaccines can save millions of lives. However, the fact that anaphylaxis might occur after vaccination has raised much concern. Currently, Centers for Disease Control and Prevention (CDC) reported the rate of 2.5–4.7 cases/million mRNA vaccine doses administered. The allergen(s) causing these reactions remain unknown. Polyethylene glycol (PEG) has surfaced as a possible elicitor, considering that this ingredient has previously been identified as an allergen.[1–3]

The European Anaphylaxis Registry is a database of anaphylaxis cases collected from more than a hundred tertiary allergy centres from twelve European countries and Brazil.[4] Herein, the data from 13,354 cases, reported between 2007 and 2020 was screened to identify reactions caused by vaccination or PEG. Table 1 presents anaphylaxis cases caused by vaccination; 14 of such reactions were reported (14/2350; 0.6% of all reactions caused by drugs). The majority of them were observed in children (10/14). Four patients had an atopic background. Reactions to all major types of vaccines were reported. More than half of the reactions (8/13) occurred within 10 min after immunization; however, four reactions had a delayed onset (>1 h). Six reactions were classified as moderate and eight reactions as severe.[5]

Table 2 presents data on reactions to PEG. Six reactions to PEG and one to polysorbate (a possibly cross-reactive allergen) were identified (7/2350; 0.3% of all drug-induced anaphylaxis cases). All patients were adults. An atopic background was reported in three cases. The basal tryptase was within normal range in all patients with available data (4/4). The time between exposure and onset of the symptoms was within half an hour (6/6). All reactions manifested with skin and cardiovascular symptoms, two of them were classified as severe and five as moderate.[5]

The Anaphylaxis Registry is not a population-based database, and it is not suitable to estimate incidence. However, a very low number of reactions reported to vaccinations (14/13,354) or PEG (6/13,354) suggests that these reactions are very rare, confirming previously published data (incidence of anaphylaxis to vaccination in the USA was recently estimated as 1.3/1,000,000).[6] The reactions to PEG in the registry might be underreported (and reported as idiopathic anaphylaxis or misdiagnosed, for example as anaphylaxis to corticosteroids, paclitaxel or local anaesthetics), as PEG is a commonly used additive, which might have been ‘overlooked’ in some cases.

The rate of patients with an atopic background in our study [29% (4/14) for vaccine and 43% (3/7) for PEG anaphylaxis] was very similar to the one reported by CDC (29%; 6/21)[7] and in the currently published case series of 10 Danish patients allergic to PEG (30%; 3/10).[2] This rather low rate of patients with an atopic background, might suggest that these reactions have distinct/additional pathomechanisms[8,9] than, for example common food anaphylaxis. Our study does not suggest that mastocytosis is an underlying disease in these reactions.

Vaccines are an extremely effective method to prevent illnesses and death, and they are safe from an allergist’s point of view with only very rare instances of severe reactions. Nevertheless, partially due to misleading information, many patients with allergies feel anxious in terms of getting the SARS-CoV-2 vaccination.[10] This might lead to lower immunization rate and hence higher mortality and morbidity due to this now preventable disease. Therefore, identifying whether PEG is the antigen responsible and determining the mechanisms of these reactions are of great importance. Here, more data on the cases (including data on comprehensive allergological work-up) should be urgently made available to help the scientific community to identify the patients who are truly at risk and thus raise the acceptance of the vaccine.

Acknowledgements

We thank all patients, parents and their children for their support in providing data. We thank all centres for patient counselling and data entry into the European Anaphylaxis Registry. The participating centres are listed on www.anaphylaxis.net.

Conflict of interest

MW declares the receipt of honoraria or consultation fees by the following companies: ALK-Abelló Arzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Regeneron Pharmaceuticals, DBV Technologies S.A, Stallergenes GmbH, HAL Allergie GmbH, Allergopharma GmbH & Co.KG, Bencard Allergie GmbH, Aimmune GmbH.

DOI: 10.1111/jdv.17326

3 Lau W, Donyai P. Knowledge, attitude and advice-giving behaviour of community pharmacists regarding topical corticosteroids. Pharmacy 2017; 5: 41.
4 Illard AN, Stratman EJ. Assessment of topical corticosteroid prescribing, counseling, and communication among dermatologists and pharmacists. JAMA Dermatol 2019; 155: 838–843.
5 Smith SD, Lee A, Blaszczynski A, Fischer G. Pharmacists’ knowledge about use of topical corticosteroids in atopic dermatitis: Pre and post continuing professional development education: Pharmacist knowledge of topical steroids. Australas J Dermatol 2016; 57: 199–204.
6 Cheong JY, Hie SL, Koh EW, Souza NNA, Koh MJ. Impact of pharmacists’ counseling on caregiver’s knowledge in the management of pediatric atopic dermatitis. Pediatr Dermatol 2019; 36: 105–109.

35, e619–e698 © 2021 European Academy of Dermatology and Venereology
| Age       | Sex | Vaccination                                                                 | Country | Interval | Severity‡ | Symptoms                                      | Atopic comorbidities | Diagnostic procedures |
|-----------|-----|------------------------------------------------------------------------------|---------|----------|-----------|------------------------------------------------|----------------------|----------------------|
| 2 months  | F   | Pentavalent vaccine (diphtheria, pertussis, tetanus, Haemophilus influenzae type b. (Hib) and hepatitis B) | Brazil§ | >2 h     | II        | Urticaria, angioedema Dyspnoea                  | None                 | Not performed        |
| 4 months  | M   | Pentavalent vaccine (diphtheria, pertussis, tetanus, Hib and hepatitis B), Inactivated polio vaccine, Pneumococcal conjugate vaccine (PCV13) | Brazil§ | <10 min  | II        | Rhinitis Vomiting Wheezing                      | Food allergy         | slgE                 |
| 1         | F   | Tetra viral vaccine (measles, mumps, rubella and varicella vaccine)          | Brazil§ | 30-60 min| III       | Vomiting Wheezing Reduction of alertness        | None                 | Neg. prick test pos. i.d. test |
| 1         | F   | Influenza                                                                   | Brazil§ | >2 h     | II        | Urticaria, angioedema Dyspnoea                  | None                 | Not performed        |
| 1         | M   | Measles Yellow fever                                                         | France  | <10 min  | III       | Cough, cyanosis Hypotension, tachycardia        | None                 | Neg. prick and i.d. test |
| 2         | M   | DTP ( diphtheria, tetanus, pertussis) | Brazil§ | <10 min  | III       | Erythema Stridor Reduction of alertness        | AD, ARC, asthma      | Not performed        |
| 3         | F   | Pneumococcal polysaccharide vaccine 23                                      | France  | <10 min  | III       | Urticaria, angioedema Wheezing Hypotension      | None                 | Neg. prick test pos. i.d. test |
| 5         | M   | Yellow fever                                                                 | Brazil§ | <10 min  | II        | Urticaria, angioedema Abdominal pain, nausea    | ARC, asthma, food allergy to egg | Pos. prick test and slgE to egg |
| 17        | M   | Hepatitis A + B                                                              | Germany | Unknown  | II        | Urticaria, angioedema Nausea, diarrhoea         | None                 | Unknown†             |
| 21        | M   | Rabies                                                                       | Germany | <10 min  | III       | Erythema, pruritus Nausea, vomiting Dizziness, hypotension, Tachycardia | Unknown | Pos. slgE to gelatin (CAP class 4) |
| 22        | F   | Rabies                                                                       | Germany | <10 min  | II        | Urticaria, angioedema Abdominal pain, diarrhoea | None                 | Not performed        |
| 23        | F   | Hepatitis B                                                                  | Switzerland | <10 min  | II        | Erythema Reduction of alertness                 | None                 | Not performed        |
| 27        | F   | Influenza                                                                    | Austria  | 1-2 h    | III       | Pruritus, urticaia Dyspnoea, wheezing Hypotension, loss of consciousness  | Asthma               | Neg. prick test pos. i.d. test |
| 47        | F   | Influenza                                                                    | Germany  | >2 h     | III       | Angioedema Dyspnoea Dizziness, hypotension      | None                 | Not performed        |

AD, atopic dermatitis; ARC, allergic rhinoconjunctivitis.†Cases fulfilling the modified NIAID/FAAN criteria described in Ref. 4.‡Severity was classified according to grading by Brown§ (II – moderate; III – severe).§The collaborating centre in Brazil is a reference centre for allergic reactions to vaccines resulting in a relatively high number of reactions to vaccines reported from this country.¶This questions were not asked in the older version of questionnaire when the case was reported.

Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH, Novartis AG, Biotest AG., AbbVie Deutschland GmbH & Co. KG and Lilly Deutschland GmbH; outside the submitted work. MBB reports personal fees (advisory board or speaker fee) from Alk-Abello, GSK, Novartis, Menarini, Sanofi-Aventis; outside the submitted work. KSH reports personal fees (advisory board or speaker fee) from Sanofi-Aventis, Novartis, Shire, Menarini and Allergopharma; outside the submitted work.
Table 2 Anaphylaxis† to PEG and polysorbate

| Age | Sex | Substance | Country | Interval | Severity | Symptoms                          | Atopic comorbidities | Baseline tryptase | Diagnostic procedures |
|-----|-----|-----------|---------|----------|----------|-----------------------------------|----------------------|-------------------|----------------------|
| 26  | F   | PEG       | Germany | <10 min  | II       | Erythema, pruritus, urticaria      | ARC, asthma          | 4 μg/l            | Not performed       |
| 34  | M   | PEG       | Italy   | 10–30 min| II       | Urticaria                         | Asthma               | Unknown          | Neg. prick pos. i.d. test |
| 40  | F   | PEG       | France  | <10 min  | III      | Urticaria, Hypotension            | None                 | 4 μg/l            | Neg. prick          |
| 42  | F   | PEG (as additive in medroxyprogesterone-acetat depo injection) | Germany | <10 min  | II       | Pruritus, rinitis, Nausea, Tachycardia | None                 | 1 μg/l            | Neg. prick pos. i.d. test |
| 50  | M   | PEG       | France  | Unknown  | III      | Pruritus, urticaria, Loss of consciousness | None                 | Unknown          | Pos. prick test and oral provocation |
| 50  | M   | Polysorbate | Switzerland | <10 min | II       | Urticaria, Dizziness, Sight disorder | ARC                  | 3 μg/l            | Pos. prick test and oral provocation |
| 67  | F   | PEG       | France  | <10 min  | II       | Urticaria, angioedema, Dizziness   | None                 | Unknown          | Pos. prick neg. i.d. test |

AD, atopic dermatitis; ARC, allergic rhinoconjunctivitis.

†Cases fulfilling the modified NIAID/FAAN criteria described in Ref. 4; additionally, two mild reactions were reported in the registry (patients with skin symptoms only, not fulfilling the inclusion criteria; both patients were women with atopic background; data not shown). ¶Severity was classified according to grading by Brown5 (II – moderate; III – severe)

The rest of the authors declare that they have no relevant conflicts of interest.

Funding source
The Anaphylaxis Registry is supported by The Network for Online Registration of Anaphylaxis NORA e. v. MW and SDB are supported by the German Research Foundation (KFO 339).

Author contributions
MK performed data analysis and wrote the manuscript. JMR, LFE, AK, MBB, KSH and SDB collected the data, contributed to the interpretation of data and revised the manuscript critically for important intellectual content. MW managed data acquisition, contributed to the interpretation of data and revised the manuscript critically for important intellectual content. All authors approved the final version of the manuscript for publication.

M. Kraft,1,2 J.M. Renaudin,3 L.F. Ensina,4 A. Kleinheinz,5 M.B. Bilò,6 K. Scherer Hofmeier,7 S. Dolle-Bierke,1 M. Worm1,4,*

1Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany, 2Department of Emergency Medicine, University Hospital Halle (Saale), Medical Faculty of Martin Luther University Halle-Wittenberg, Halle, Germany, 3Presidency on behalf of Allergy Vigilance Network, Vandœuvre les Nancy, France, 4Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil, 5Department of Dermatology, Elbe Medical Centre, Buxtehude, Germany, 6Department of Clinical and Molecular Sciences, Marche Polytechnic University – Allergy Unit, University Hospital Ospedali Riuniti di Ancona, Ancona, Italy, 7Division of Allergy, Department of Dermatology, University Hospital Basel, University of Basel, Basel, Switzerland

*Correspondence: M. Worm. E-mail: margitta.worm@charite.de

References
1 Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021. JAMA 2021; 325: 1101
2 Brousgaard-Mouritsen MA, Johansen JD, Garvey LH. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients. Clin Exp Allergy 2021; 51: 463–470.
3 Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anaesthesia 2021; 126: e106–e108.
4 Kraft M, Scherer Hofmeier K, Rueff F et al. Risk Factors and characteristics of biphasic anaphylaxis. J Allergy Clin Immunol Pract 2020; 8: 3388–3395.e6.
5 Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114: 371–376.
6 McNeill MM, Weintraub ES, Duffy J et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2016; 137: 868–878.
7 CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States. December 14–23, 2020. MMWR Morb Mortal Wkly Rep 2021; 70: 46–51. https://doi.org/10.15585/mmwr.mm7002e1
8 Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev 2020; 154–155: 163–175.
9 Wernande E, Garvey LH. Immediate type hypersensitivity to polyethylene glycol: a review. Clin Exp Allergy 2016; 46: 907–922.
Stevens–Johnson syndrome induced by tonic water

Editor

Tonic water is known to cause fixed eruptions (FEs), but severe drug eruption is rarely reported to date. Here we describe the first case of Stevens–Johnson syndrome (SJS) induced by intake of tonic water. We must notice that the FE induced by tonic water can be severe due to repeated intake.

A 26-year-old man presented with a 1-year history of a recurrent rash. He noticed that the symptom had appeared one day after drinking gin and tonic and regressed within a week leaving hyperpigmentation. At first, the lesion was an erythematous plaque on his upper lip, and the extent of the lesion had spread to most of his body surface as the symptoms had relapsed. Physical examination revealed high fever (39.6 °C), erosions on his lips and scrotum, and generalized, ill-defined, coalescing, erythematous macules (Fig. 1). A biopsy of the lesion revealed vacuolization of the basal cell layer, necrosis of keratinocytes surrounded by lymphocytes and a sparse perivascular lymphoid infiltrate, confirming the diagnosis of SJS. He was treated orally with corticosteroids, and the rash had resolved leaving hyperpigmentation. The corticosteroids were tapered and finished after the symptom regressed.

One month later, a closed patch test (PT) was conducted with several kinds of tonic water (Schweppes® [Coca-Cola, Tokyo, Japan], CANADA DRY® [Coca-Cola] and Wilkinson® [Asahi, Tokyo, Japan]), gin, quinine (20% in petrolatum), quinine chloride (20% in petrolatum) and optical isomers of quinine (quinidine and hydroxychloroquine, 20% in petrolatum) on both affected and unaffected skin areas with positive results only to quinine and quinine chloride on the affected skin according to criteria of The International Contact Dermatitis Research Group. The erythema and infiltration extended around both of the test sites (Fig. 2). Lymphocyte stimulation tests (LSTs) with quinine and quinine chloride were negative. The diagnosis of SJS induced by tonic water was made. We did not perform an oral challenge test (OCT) due to severity of his symptom.

Quinine is an antimalarial drug, and tonic water was developed to ease the bitter taste of quinine by adding sugar and citrus extract. Various manifestations of hypersensitivity to quinine, and tonic water including quinine, have been reported. Although immediate reactions such as anaphylaxis and allergic urticaria are reported, the most reported hypersensitivity to tonic water is FE. It typically involves the lips, appears after drinking tonic water and disappears spontaneously, leaving residual hyperpigmentation. The symptoms are usually recurrent because patients are not aware that tonic water is an allergen. Repeated intake of tonic water can worsen the extent of eruptions but they rarely progress to severe eruptions such as toxic epidermal necrolysis (TEN) and generalized bullous fixed eruption (GBFE).

Stevens–Johnson syndrome is a life-threatening cutaneous hypersensitivity reaction, typically to a medication. SJS induced by food has been rarely reported. Patch tests and OCTs are useful to identify tonic-water-induced eruptions. We searched for tests conducted in 23 previously published cases of FEs, and in a case of GBFE and TEN, due to tonic water, in the English and Japanese literature. LSTs were negative in the two cases tested. PTs on unaffected skin were 52.6% (10/19) positive. PTs on affected regions were 33.3% (3/9) positive by tonic water, while 61.5% (8/13) was positive by quinine. OCTs were 100% (15/15) positive. However, some cases needed further corticosteroid therapy to treat the eruption re-provoked by the OCT. These results suggest that PTs on affected regions, especially using quinine, are useful to confirm the diagnosis of tonic-water-induced eruptions.

This is the first report of SJS induced by tonic water. We emphasize that FEs can progress to SJS and patients must be educated to avoid suspected foods.

Acknowledgements

The patient in this manuscript has given written informed consent to publication of his case details.

Figure 1 Clinical images of Stevens–Johnson syndrome induced by tonic water; (a) an erosion on the patient’s scrotum, and (b) erythematous macules on his trunk.